Albany Molecular Research (AMRI) and Arbutus Biopharma (ABUS) Head-To-Head Review

Albany Molecular Research (NASDAQ: AMRI) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Valuation and Earnings

This table compares Albany Molecular Research and Arbutus Biopharma’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Albany Molecular Research N/A N/A N/A ($1.43) -15.20
Arbutus Biopharma $1.50 million 176.16 -$384.16 million ($4.97) -0.97

Albany Molecular Research has higher earnings, but lower revenue than Arbutus Biopharma. Albany Molecular Research is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Albany Molecular Research and Arbutus Biopharma, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Albany Molecular Research 0 4 0 0 2.00
Arbutus Biopharma 0 1 5 0 2.83

Albany Molecular Research presently has a consensus price target of $18.00, indicating a potential downside of 17.20%. Arbutus Biopharma has a consensus price target of $13.00, indicating a potential upside of 170.83%. Given Arbutus Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Arbutus Biopharma is more favorable than Albany Molecular Research.

Risk and Volatility

Albany Molecular Research has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Insider & Institutional Ownership

72.1% of Albany Molecular Research shares are held by institutional investors. Comparatively, 60.0% of Arbutus Biopharma shares are held by institutional investors. 14.5% of Albany Molecular Research shares are held by insiders. Comparatively, 6.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Albany Molecular Research and Arbutus Biopharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Albany Molecular Research -5.93% -13.39% -3.42%
Arbutus Biopharma N/A -34.98% -24.76%

Albany Molecular Research Company Profile

Albany Molecular Research, Inc. is a contract research and manufacturing company. The Company operates through Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) segments. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing. The API segment includes pilot to commercial scale manufacturing of active pharmaceutical ingredients and intermediates. The DP segment includes pre-formulation, formulation and process development through commercial scale production of complex liquid-filled and lyophilized sterile injectable products and ophthalmic formulations. The FC segment includes lab to commercial scale synthesis of reagents and diverse compounds. It supplies a range of services and technologies supporting the discovery and development of pharmaceutical products, the manufacturing of API and drug product for new and generic drugs.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Receive News & Ratings for Albany Molecular Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply